Viewing Study NCT02482259


Ignite Creation Date: 2025-12-24 @ 3:06 PM
Ignite Modification Date: 2026-01-27 @ 12:59 AM
Study NCT ID: NCT02482259
Status: COMPLETED
Last Update Posted: 2017-09-15
First Post: 2015-06-12
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
Sponsor: Newcastle-upon-Tyne Hospitals NHS Trust
Organization:

Study Overview

Official Title: Assessment of Frailty in Patients With Advanced Hepatocellular Cancers
Status: COMPLETED
Status Verified Date: 2017-09
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: FAC-L
Brief Summary: This study is looking at the feasibility of performing frailty assessments on patients with advanced hepatocellular cancer.
Detailed Description: This study is primarily looking to see if it is feasible to assess frailty in patients with advanced hepatocellular cancer. It is also evaluating whether there may be any correlation between these assessments and toxicity of treatment and outcome.

The assessments include: Frailty score, nutritional assessment, comorbidity score and quality of life. In addition sarcopenia will be assessed measuring muscle mass from imaging performed as part of routine clinical care.

The assessments will be performed at baseline on entry into the study, at week 9 and week 18.

There is the option for patients to also donate a blood samples for research purposes.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: